Cited by 138Diabetes and associated disordersAdrenal Hormones and DisordersDiabetes Management and Research

Insulin Autoimmune Syndrome (Hirata Disease): A Comprehensive Review Fifty Years After Its First Description

Open access
Cappellani, Daniele, Macchia, Enrico, Falorni, Alberto, Marchetti, Piero·2020·Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

Abstract

Insulin autoimmune syndrome (IAS), also named Hirata's disease, is a rare condition characterized by hypoglycemic episodes due to the presence of high titers of insulin autoantibodies (IAA). IAS is a form of immune-mediated hypoglycemia, which develops when a triggering factor (ie, a medication or a viral infection) acts on an underlying predisposing genetic background. IAS pathogenesis involves the formation of insulin-IAA complexes that induce glycemic alterations with a double-phase mechanism: IAA prevent insulin to bind its receptor in the postprandial phase, possibly resulting in mild hyperglycemia; thereafter, insulin is released from the complexes irrespective of blood glucose concentrations, thus inducing hypoglycemia. The diagnosis of IAS is challenging, requiring a careful workup aimed at excluding other causes of hyperinsulinemic hypoglycemia. The gold standard for the definitive diagnosis is the finding of IAA in a blood sample. Because IAS is frequently a self-remitting disease, its management mostly consists of supportive measures, such as dietary modifications, aimed at preventing the development of hypoglycemia. Pharmacological therapies may occasionally be necessary for patients presenting with severe manifestations of IAS. Available therapies may include drugs that reduce pancreatic insulin secretion (somatostatin analogues and diazoxide, for instance) and immunosuppressive agents (glucocorticoids, azathioprine and rituximab). The purpose of this review is to provide a comprehensive analysis of the disease, by describing the burden of knowledge that has been obtained in the 50 years following its first description, took in 1970, and by highlighting the points that are still unclear in its pathogenesis and management.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/dmso.s219438

Cites

125 of 125 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • IAA that develop after exogenous insulin analog administration rarely cause IAS, because they tend to be characterized by a lower insulin binding capacity and higher affinity.

    “Of note, IAA that develop after exogenous insulin analog administration rarely cause IAS, because they tend to be characterized by a lower insulin binding capacity and higher affinity [73].”

    From Non-Diabetic Hypoglycemia: Evaluation and Management in Adults (2025) · cites this paper as [73]

    The Pathogenesis section says antibodies that develop after exogenous insulin exposure usually have higher affinity and lower binding capacity and rarely cause glycemic disturbances. But it distinguishes those antibodies from IAA, which it defines as antibodies against native endogenous insulin; the claim incorrectly calls the exogenous-insulin antibodies IAA and says they rarely cause IAS rather than glycemic disturbances. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • The mismatch between insulin bioavailability and blood glucose levels is central to the pathogenesis of IAS-induced hypoglycemia.

    “This mismatch between insulin bioavailability and blood glucose levels is central to the pathogenesis of IAS-induced hypoglycemia [73].”
  • Antecedent viral infections with measles, mumps, rubella, cocksakie B, and varicella zoster viruses have been implicated in IAS by stimulating a robust immune response.

    “Antecedent viral infections with measles, mumps, rubella, cocksakie B, and varicella zoster viruses have been implicated by stimulating a robust immune response [73].”
  • The pathogenesis of IAS involves the production of IAA with high insulin binding capacity but low affinity.

    “The pathogenesis of IAS involves the production of IAA with high insulin binding capacity but low affinity [73].”
  • Immunosuppression with glucocorticoids, azathioprine, and rituximab have been found helpful in severe IAS, although use is mostly limited to case reports and long-term outcomes are unknown.

    “Immunosuppression with glucocorticoids, azathioprine, and rituximab have all been found to be helpful in severe cases, although their use is mostly limited to case reports, and long-term outcomes are unknown [73].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

6 of the 131 references couldn’t be matched to a known paper.

Research works printed but not linked: 4

  1. [1]Hirata Y, Ishizu H, Ouchi N. Insulin autoimmunity in a case of spontaneous hypoglycemia. J Jpn Diabetes Soc. 1970; 13: 312– 320.
  2. [7]Hirata Y. Insulin Autoimmune Syndrome - the second case. J Jpn Diabetes Soc. 1972; 15: 187– 192.
  3. [29]Takei M. Insulin auto-antibodies produced by methimazole treatment in the patients with the Graves’ disease. J Tokyo Women’s Med Coll. 1980; 50: 54.
  4. [81]Eguchi Y. Scatchard analysis of insulin autoantibodies in the insulin autoimmune syndrome. J Tokyo Women’s Med Coll. 1989; 59: 1286– 1305.

Cited by

Sorted by citations

Authors
Cappellani, D., Macchia, E., Falorni, A., & Marchetti, P.
Affiliations
  • University of Pisa (IT)
  • University of Perugia (IT)
Corresponding author
Cappellani, Daniele
Venue
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Published
2020-04
Volume
Volume 13
Pages
963-978
ISSN
1178-7007 (ISSN-L)
OpenAlex
W3014251084
Cited by
138
References
131
Citations by year
2026: 23 · 2025: 24 · 2024: 23 · 2023: 24 · 2022: 22 · 2021: 17 · 2020: 4 · 2019: 1
FWCI
2.39
Type
journal article
Language
en
Open access
Locations
  • Diabetes Metabolic Syndrome and Obesity (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
insulin autoimmune syndrome, insulin autoantibodies, hyperinsulinemic hypoglycemia, insulin receptor binding, somatostatin analogues, diazoxide, immunosuppressive therapy, rituximab, glucocorticoids, azathioprine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review